Skip to main content

Proteome Systems Opens Australian IPO

NEW YORK, Aug. 30 (GenomeWeb News) - Proteome Systems announced last week the opening of its AU$20 million initial public offering on the Australian Stock Exchange. The offer price, said Proteome Systems, gives the company a market capitalization of AU$120 million.

 

The size of the IPO is significantly less than Proteome Systems had initial hoped for. As reported earlier this year by ProteoMonitor, GenomeWeb News' sister publication, the company had originally planned to raise AU$45 million, a figure later cut to AU$35 million.

 

According to Proteome Systems, Patersons Securities is underwriting the offering.

 

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.